Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Allakos Inc. (ALLK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Allakos Provides Business Update and Reports First Quarter 2023 Financial Results SAN CARLOS, Calif., May 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Recent Allakos Events • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis during the first quarter of 2023. • Continued enrollment of a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria during the first quarter of 2023. Upcom..." |
|
| 04/17/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Quarterly results|
Docs:
|
"Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN CARLOS, Calif., March 6, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab and AK006. Recent Allakos Events • Initiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in the third quarter of 2022. • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patien..." |
|
| 11/29/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Quarterly results |
| 09/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, among the Company and Jefferies LLC and Cowen and Company, LLC",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation",
"Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock SAN CARLOS, Calif., September 19, 2022 - Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Alta Partners, Braidwell LP, BVF Partners L.P., Commodore Capital, Deep Track Capital, Frazier Life Sciences, New Enterprise Associates , RTW Investments, L.P., Surveyor Capital , TCGX, and Vivo Capital. Before deducting the underwriting discounts and commissions and estimated offering expenses, the company expects to receive...",
"Corporate Presentation" |
|
| 09/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/09/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis – Lirentelimab met histologic co‐primary endpoint but missed symptomatic co‐primary endpoint – SAN CARLOS, Calif., SAN CARLOS, Calif., September 9, 2022 ‐‐ Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today reported data from EoDyssey, a 24‐week, Phase 3, randomized, double‐blind, placebo‐controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis . The trial met its histologic co‐primary endpoint, but it did not achieve statistical significance on the patient reported symptomatic co‐primary endpoint, in both th..." |
|
| 08/04/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 07/25/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/20/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release is made by and between Mark Asbury and Allakos Inc. . RECITALS WHEREAS, Employee signed an offer letter with the Company for employment effective as ofNovember 8, 2018 ; WHEREAS, Employee signed an At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement with the Company on November 8, 2018 ; WHEREAS, Employee’s employment with the Company will end effective June 30, 2022 ; and NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows: COVENANTS 1. Consideration. In consideration of Employee’s agreement to remain with the Company until the Termination Date, as well as the timely execution and non-revocation of this Agreement..." |
|
| 04/05/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/01/2022 |
8-K
| Quarterly results|
Docs:
|
"Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results REDWOOD CITY, Calif., March 1, 2022 – Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Events • Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis in the fourth quarter of 2021. • Reported topline data from ENIGMA 2, a Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with eosinophilic gastritis/eosinophilic duodenitis in the fourth ..." |
|
| 02/16/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement Interactive Data |
| 02/15/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/01/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/30/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/08/2021 |
8-K
| Quarterly results |
| 10/25/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting REDWOOD CITY, Calif., October 24, 2021 -- Allakos Inc. , a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology Annual Scientific Meeting. The presentations will take place during the ACG Annual Meeting being held in Las Vegas, Nev. and virtually Oct 22 to 27, 2021. Access to all accepted ePosters and ePresentations will be available on the ACG program website and in the October online supplement to the American Journal of Gastroenterology. EG and/or EoD Prev...",
"Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation – Study shows 45% of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis – – Presentation selected for “ACG Presidential Poster Award” – REDWOOD CITY, Calif., October 25, 2021 -- Allakos Inc. , a biotechnology company developing investigational medicine lirentelimab for the treatment of eosinophil and mast cell-related diseases, today announced that its poster, “High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Unex..." |
|
| 08/09/2021 |
8-K
| Quarterly results |
| 07/23/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/07/2021 |
8-K
| Quarterly results |
| 05/26/2021 |
8-K
| Quarterly results |
| 05/24/2021 |
8-K
| Quarterly results |
| 05/10/2021 |
8-K
| Quarterly results |
|
|
|